Outlook Therapeutics, Inc. - Common Stock (OTLK)
1.0900
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 29th, 6:34 AM EDT
Detailed Quote
Previous Close | 1.090 |
---|---|
Open | - |
Bid | 1.020 |
Ask | 1.030 |
Day's Range | N/A - N/A |
52 Week Range | 0.7900 - 8.320 |
Volume | 93,303 |
Market Cap | 47.39M |
PE Ratio (TTM) | -1.912 |
EPS (TTM) | -0.6 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 5,358,956 |
Chart
About Outlook Therapeutics, Inc. - Common Stock (OTLK)
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company specializes in the research and advancement of therapies aimed at addressing significant unmet medical needs in ophthalmology. Through its proprietary drug pipeline, Outlook Therapeutics is committed to enhancing the quality of life for patients affected by various retinal conditions, striving to bring new possibilities and improved outcomes to vision care. Read More
News & Press Releases
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · August 28, 2025
Via Benzinga · August 28, 2025
Via Benzinga · August 28, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · August 28, 2025
Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Whystocktwits.com
Via Stocktwits · August 28, 2025
Outlook Therapeutics shares fall after the FDA rejects its ONS-5010 wet AMD drug application, citing insufficient efficacy evidence despite prior trial success.
Via Benzinga · August 28, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · August 28, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · August 28, 2025
Via Benzinga · August 28, 2025
Via Benzinga · August 27, 2025
Via Benzinga · August 27, 2025
Via Benzinga · August 26, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · August 18, 2025
- Video webcasts from participating companies now available here
Via ACCESS Newswire · July 22, 2025

Via Benzinga · June 6, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END
Via FinancialNewsMedia · June 4, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 23, 2025

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus cameras are sophisticated instruments utilized in ophthalmology for capturing detailed images of the retina. They employ a specialized optical design akin to an indirect ophthalmoscope, with the angle of view being a key parameter defining their functionality… Fundus photography enables physicians to meticulously examine retinal changes over time, facilitating collaboration among colleagues and enhancing patient care. A recent report from Precedence Research said: “The fundus cameras market experiences growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). Traditionally, fundus photography with film-based cameras, preferably through pharmacologically dilated pupils, has been pivotal in documenting AMD severity. The emergence of high-resolution digital cameras presents new opportunities in the market. Comparisons among different imaging systems, including nonstereoscopic color retinal images taken with digital cameras through dark-adapted and dilated pupils, as well as stereoscopic images captured with standard film cameras, highlight the expanding applications of fundus cameras. Such comparisons underscore the need for versatile imaging solutions to accommodate diverse clinical scenarios, thus fueling the growth in the fundus cameras market.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Outlook Therapeutics, Inc. (NASDAQ: OTLK), Eyenovia, Inc. (NASDAQ: EYEN), Bausch + Lomb Corporation (NYSE: BLCO), Biomea Fusion, Inc. (NASDAQ: BMEA).
By FN Media Group LLC · Via GlobeNewswire · June 4, 2025
Via Benzinga · May 22, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · May 22, 2025

Via Benzinga · February 18, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.
Via Benzinga · January 16, 2025